258 related articles for article (PubMed ID: 33240480)
1. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis.
McConnell JW; Tsang Y; Pruett J; Iii WD
Pulm Circ; 2020; 10(4):2045894020911831. PubMed ID: 33240480
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
3. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
[TBL] [Abstract][Full Text] [Related]
4. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
6. Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
Tsang Y; Singh R; Verma S; Panjabi S
Rheumatol Ther; 2023 Jun; 10(3):741-756. PubMed ID: 36959524
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.
Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S
Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609
[TBL] [Abstract][Full Text] [Related]
8. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
Manzi G; Mariani MV; Filomena D; Papa S; Recchioni T; Scoccia G; Vizza CD; Badagliacca R
Int J Cardiol; 2023 Dec; ():131691. PubMed ID: 38158135
[TBL] [Abstract][Full Text] [Related]
10. Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.
Burger CD; Tsang Y; Chivers M; Vekaria RV; Doad G; Atkins N; Panjabi S
Clinicoecon Outcomes Res; 2024; 16():447-459. PubMed ID: 38831921
[TBL] [Abstract][Full Text] [Related]
11. Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension.
McConnell J; Bilir SP; Xu Y; Tsang Y; Panjabi S
J Med Econ; 2023; 26(1):1349-1355. PubMed ID: 37800591
[TBL] [Abstract][Full Text] [Related]
12. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study.
Dean BB; Saundankar V; Stafkey-Mailey D; Anguiano RH; Nelsen AC; Gordon K; Classi P
Drugs Real World Outcomes; 2020 Sep; 7(3):229-239. PubMed ID: 32144746
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
Manzi G; Mariani MV; Filomena D; Recchioni T; Papa S; Scoccia G; Badagliacca R; Vizza CD
Vascul Pharmacol; 2024 Mar; 154():107280. PubMed ID: 38309551
[TBL] [Abstract][Full Text] [Related]
14. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.
Colglazier E; Ng AJ; Parker C; Nawaytou H; Fineman JR
J Pediatr Pharmacol Ther; 2021; 26(5):512-516. PubMed ID: 34239406
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
18. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
19. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
El Yafawi R; Wirth JA
Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
[TBL] [Abstract][Full Text] [Related]
20. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Thurber KM; Williams BM; Bates RE; Frantz RP
Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
